Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Earlier this week, Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), the commercial stage Pharma that markets and sells four different types of drugs indicated to treat Duchenne ...